XDR Tuberculosis News and Research

RSS
Extensively drug-resistant tuberculosis (XDR TB) is a relatively rare type of multidrug-resistant tuberculosis (MDR TB). It is resistant to almost all drugs used to treat TB, including the two best first-line drugs: isoniazid and rifampin. XDR TB is also resistant to the best second-line medications: fluoroquinolones and at least one of three injectable drugs (i.e., amikacin, kanamycin, or capreomycin).

Because XDR TB is resistant to the most powerful first-line and second-line drugs, patients are left with treatment options that are much less effective and often have worse treatment outcomes.

XDR TB is of special concern for persons with HIV infection or other conditions that can weaken the immune system. These persons are more likely to develop TB disease once they are infected, and also have a higher risk of death once they develop TB disease.

The risk of acquiring XDR TB in the United States appears to be relatively low. However, it is important to acknowledge the ease at which TB can spread. As long as XDR TB exists, the United States is at risk and must address the threat.
WHO, Stop TB Partnership, UNITAID announce new tuberculosis test that quickly diagnoses MDR-TB

WHO, Stop TB Partnership, UNITAID announce new tuberculosis test that quickly diagnoses MDR-TB

New test quickly detects multi drug-resistant tuberculosis

New test quickly detects multi drug-resistant tuberculosis

The focus on HIV/AIDS has helped forget the threat of tuberculosis

The focus on HIV/AIDS has helped forget the threat of tuberculosis

Hard to treat TB case diagnosed in Britain

Hard to treat TB case diagnosed in Britain

Anti-tuberculosis drug resistance in the world

Anti-tuberculosis drug resistance in the world

Aggressive TB control can yield big economic gains

Aggressive TB control can yield big economic gains

First genome sequence of  XDR strain of the bacterium Mycobacterium tuberculosis

First genome sequence of XDR strain of the bacterium Mycobacterium tuberculosis

Global public health security in the 21st century

Global public health security in the 21st century

WHO says more killer diseases like AIDS on their way

WHO says more killer diseases like AIDS on their way

TB jetsetter not as dangerous as first thought

TB jetsetter not as dangerous as first thought

WHO ready to tackle drug resistant TB

WHO ready to tackle drug resistant TB

New plan to contain extensively drug-resistant TB (XDR-TB)

New plan to contain extensively drug-resistant TB (XDR-TB)

NIAID to tackle drug resistant TB

NIAID to tackle drug resistant TB

TB jet traveller case...just how competent are U.S. authorities at protecting the public?

TB jet traveller case...just how competent are U.S. authorities at protecting the public?

Public health ethics expert on quarantine order for tuberculosis patient

Public health ethics expert on quarantine order for tuberculosis patient

Trans-Atlantic air traveler in quarantine with dangerous TB

Trans-Atlantic air traveler in quarantine with dangerous TB

Stop TB Partnership aims to treat 50 million patients between 2006 and 2015

Stop TB Partnership aims to treat 50 million patients between 2006 and 2015

Extremely drug resistant TB a serious problem in India

Extremely drug resistant TB a serious problem in India

Towards universal access: scaling up priority HIV/AIDS interventions in the health sector

Towards universal access: scaling up priority HIV/AIDS interventions in the health sector

Lesotho struggles to contain spread of tuberculosis

Lesotho struggles to contain spread of tuberculosis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.